Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)

NCT06441006 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT06441006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06441006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)
Lead sponsor
University of California, San Francisco
Phase
Phase 2/3
Overall status
Recruiting
Start date
October 3, 2025
Completion date
August 31, 2031
Enrollment
400 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis, mdr, tuberculosis, multidrug-resistant, tuberculosis, pulmonary